文献速递重症综合管理与镇静镇痛

重症随机试验的效能偏倚与临床重要治疗效应

Powering Bias and Clinically Important Treatment Effects in Randomized Trials of Critical Illness.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论多数高影响力重症试验因高估对照组死亡率并假设不现实的治疗效应,导致结果偏向无效,无法排除临床重要获益或伤害。

该二次分析纳入2008-2018年发表在高影响力期刊的101项以死亡率为主要终点的多中心成人重症随机试验。多数试验(77.3%)在效能计算中高估对照组死亡率(观察值减预测值 -6.7% ± 9.8%;p < 0.01),14项试验中干预需预防至少一半死亡才能达到假设效应。仅12项试验主要终点达统计学显著,5项显示干预相关死亡率增加。47.0%的试验按绝对风险降低≥10%设计效能,但仅3项试验观察到统计学显著的治疗获益。67.3%的试验无法排除临床重要获益或伤害。

要点

  • 77.3%的重症试验高估对照组死亡率,观察值与预测值差值 -6.7% ± 9.8%(p < 0.01),使结果偏向无效。
  • 14项试验中,干预需预防至少一半死亡才能达到假设治疗效应。
  • 47.0%的试验按绝对风险降低≥10%设计效能,但仅3项试验观察到统计学显著获益。
  • 仅12项试验主要终点达统计学显著,其中5项显示干预相关死亡率增加。
  • 67.3%的试验无法排除临床重要治疗获益或伤害。

适用人群与场景

  • 2008-2018年发表在高影响力期刊的多中心成人重症随机试验,以死亡率为主要终点。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心随机试验的二次分析;样本量:101项试验;人群:成人重症患者;干预与对照:无(观察性分析);主要终点:研究特定随访间隔的死亡率风险差。
  • 77.3%的试验在效能计算中高估对照组死亡率,观察值减预测值为 -6.7% ± 9.8%(p < 0.01)。
  • 14项试验中,干预需预防至少一半死亡才能达到假设治疗效应。
  • 7项试验预设了适应性样本量策略,可能缓解该问题。
  • 20项试验观察到的死亡率风险差在预测值5%以内,其中16项未达统计学显著。
  • 47.0%的试验按绝对风险降低≥10%设计效能,但仅3项试验观察到统计学显著的治疗获益。
  • 12项试验主要终点达统计学显著,其中5项显示干预相关死亡率增加。
  • 67.3%的试验无法排除临床重要治疗获益或伤害。

证据类型、等级与局限

  • 证据类型:多中心随机试验的二次分析;证据等级或推荐强度:原文未提及;局限:原文未述局限性。

对床旁实践的改变

  • 解读高影响力重症试验时需注意对照组死亡率常被高估,可能导致结果偏向无效;不能仅凭统计学不显著排除临床重要治疗效应。

指南或共识出处

  • Crit Care Med

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Recurring issues in clinical trial design may bias results toward the null, yielding findings inconclusive for treatment effects. This study evaluated for powering bias among high-impact critical care trials and the associated risk of masking clinically important treatment effects.

DESIGN, SETTING, AND PATIENTS: Secondary analysis of multicenter randomized trials of critically ill adults in which mortality was the main endpoint. Trials were eligible for inclusion if published between 2008 and 2018 in leading journals. Analyses evaluated for accuracy of estimated control group mortality, adaptive sample size strategy, plausibility of predicted treatment effect, and results relative to the minimal clinically important difference. The main outcome was the mortality risk difference at the study-specific follow-up interval.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Of 101 included trials, 12 met statistical significance for their main endpoint, five for increased intervention-associated mortality. Most trials (77.3%) overestimated control group mortality in power calculations (observed minus predicted difference, -6.7% ± 9.8%; p < 0.01). Due to this misestimation of control group mortality, in 14 trials, the intervention would have had to prevent at least half of all deaths to achieve the hypothesized treatment effect. Seven trials prespecified adaptive sample size strategies that might have mitigated this issue. The observed risk difference for mortality fell within 5% of predicted in 20 trials, of which 16 did not reach statistical significance. Half of trials (47.0%) were powered for an absolute risk reduction greater than or equal to 10%, but this effect size was observed in only three trials with a statistically significant treatment benefit. Most trials (67.3%) could not exclude clinically important treatment benefit or harm.

CONCLUSIONS: The design of most high-impact critical care trials biased results toward the null by overestimating control group mortality and powering for unrealistic treatment effects. Clinically important treatment effects often cannot be excluded.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Abrams D, Montesi SB, Moore SKL, et al. Powering Bias and Clinically Important Treatment Effects in Randomized Trials of Critical Illness. Crit Care Med. 2020. PMID: 33031148. doi:10.1097/CCM.0000000000004568

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。